Janssen Biotech Inc.
800 Ridgeview Drive
Horsham
Pennsylvania
19044
United States
Tel: 888-227-5624
246 articles about Janssen Biotech Inc.
-
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
-
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
3/16/2022
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech, Inc.
-
The end of February picks up significantly from early this year for the U.S. Food and Drug Administration and its PDUFA dates.
-
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
2/11/2022
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million.
-
Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.
-
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
2/3/2022
Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover novel ADCs for three targets.
-
Genocea Biosciences Provides Corporate Update
1/4/2022
Genocea Biosciences, Inc. has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in the context of vaccine therapies for cancer.
-
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
12/17/2021
Dyadic International, Inc. announced that it has entered into a Research, License and Collaboration Agreement (“Agreement”) with Janssen Biotech, Inc. (‘’Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions
12/6/2021
Kaleido Biosciences, Inc. today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”).
-
Philogen Announces New Collaboration with Janssen To Discover Small Molecule Therapeutics
11/24/2021
Philogen S.p.A. has entered into a new collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecules of pharmaceutical interest utilizing Philochem’s novel lead-generation technologies.
-
The drug makers have until February 28, 2022 to review their findings and analytical processes for the drug they are developing to treat relapsed and/or refractory multiple myeloma.
-
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen
10/26/2021
Protagonist Therapeutics, Inc. today announced that it will receive a $7.5 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235 (JNJ-2113).
-
The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.
-
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
10/20/2021
F-star Therapeutics, Ltd. today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
VisualDx Announces Collaboration with Janssen to Pilot New API and Bring Equitable AI to the Point of Care
10/18/2021
VisualDx, a global leader in web-based clinical decision support, announced that it has entered into an agreement with Janssen Biotech, Inc., one of the pharmaceutical companies of Johnson & Johnson.
-
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
10/4/2021
Xencor, Inc. today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc. to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor.
-
The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.
-
Persephone Biosciences Inc. Announces Collaboration with Janssen Biotech, Inc.
9/21/2021
Persephone Biosciences Inc., today announced that it has entered into a collaboration agreement with Janssen Biotech, Inc.
-
Izencitinib was generally well tolerated and its safety data were consistent with expectations, but it failed to achieve its primary endpoint. Here's more about it.
-
It was based on data from the APOLLO trial showing the drug significantly decreased the risk of progression or death by 37% compared to dexamethasone alone.